In 2013 the venture capital raised by Biotechnology companies in Canada almost doubled (93% increase) compared to the previous year’s figure, to reach a total of USD 139m. The majority of Biotech products in the industry belong to the area of oncology, followed by products developed for nervous system and for Infectious diseases indications. Distributors, … Continue reading Canadian Life Sciences Trend Analysis 2014
In 2013, the total venture financing value amassed by Danish Biotechnology companies was by 64% increased compared to the previous year’s figure (USD 82m in 2013 compared to USD 50m in 2012). This summer’s snapshot of the Danish biotech industry reveals that 1 in 10 biotech companies are publicly traded; a 4 percentage point increase … Continue reading Danish Life Sciences Trend Analysis 2014
2013 saw the Swedish Biotech Industry raising a significantly smaller venture financing amount than in the year before (USD 27m compared to USD 127m in 2012). During the same period the number of companies achieving an IPO exit doubled. The number of biotech products in Phase I of development remained stable compared to last year, … Continue reading Swedish Life Sciences Trend Analysis 2014
